2002

1. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)

   AIDS, Vol. 16, Núm. 11, pp. 1554-1556